NCT04324151View on ClinicalTrials.gov

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

RecruitingOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

March 24, 2020

Primary Completion Date

December 24, 2024

Study Completion Date

March 24, 2025

Conditions
Non Small Cell Lung Cancer
Trial Locations (1)

410013

RECRUITING

Yongchang Zhang, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT04324151 - Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC | Biotech Hunter | Biotech Hunter